List view / Grid view
Novartis announced that the US Food and Drug Administration licensed…
16 June 2014 | By Novartis
Novartis announced that the US Food and Drug Administration licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines...
Novartis announced that its meningococcal serogroup B vaccine, Bexsero®, will…
24 February 2014 | By Novartis
Novartis announced that its meningococcal serogroup B vaccine, Bexsero®, will be used as part of a vaccination program at the University of California Santa Barbara and will end on March 7...
Novartis supplies MenB vaccine for a vaccination program at Princeton,…
9 December 2013 | By Novartis
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials...
85% of subjects immunologically protected after receiving second dose of…
14 November 2013 | By Novartis
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant...
The Australian Therapeutic Goods Administration (TGA) has added Bexsero® to…
15 August 2013 | By Novartis
The Australian Therapeutic Goods Administration (TGA) has added Bexsero® to the Australian Register of Therapeutic Goods (ARTG)...
Novartis announced that the US FDA approved Menveo®...
1 August 2013 | By Novartis
Novartis announced that the US FDA approved Menveo®...
Following JCVI interim recommendation on Novartis Bexsero® vaccine...
24 July 2013 | By Novartis
Following JCVI interim recommendation on Novartis Bexsero® vaccine...
Bexsero®, first vaccine to prevent the leading cause of life-threatening…
22 January 2013 | By Novartis
Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe...
Findings from a pivotal Phase III clinical trial...
14 January 2013 | By Novartis
Findings from a pivotal Phase III clinical trial...
The US FDA approved the use of Flucelvax®...
20 November 2012 | By Novartis
The US FDA approved the use of Flucelvax®...
The CHMP of the EMA has adopted a positive opinion…
16 November 2012 | By Novartis
The CHMP of the EMA has adopted a positive opinion for Bexsero for use in individuals from 2 months of age and older...
Novartis welcomes the decisions by Health Canada and Swiss Agency…
31 October 2012 | By Novartis
Novartis welcomes the decisions by Health Canada and Swiss Agency for Therapeutic Products, Swissmedic...
Novartis announced that it completed the transaction to acquire an…
22 March 2011 | By Novartis
Novartis announced that it completed the transaction to acquire an 85 percent stake in Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd...
The FDA approval of Menveo for use in children 2…
31 January 2011 | By Novartis
The FDA approval of Menveo for use in children 2 to 10 years of age is based on Phase III trial data involving 5,297 participants in that age group...
